bluuebunny/crossref_metadata_2025 huggingface dataset:
Supplementary Figure 5 from Combined Therapy with Mutant-Selective EGFR Inhibitor and Met Kinase Inhibitor for Overcoming Erlotinib Resistance in EGFR-Mutant Lung Cancer
Authors: Nakagawa Takayuki , Takeuchi Shinji , Yamada Tadaaki , Nanjo Shigeki , Ishikawa Daisuke , Sano Takako , Kita Kenji , Nakamura Takahiro , Matsumoto Kunio , Suda Kenichi , Mitsudomi Tetsuya , Sekido Yoshitaka , Uenaka Toshimitsu , Yano Seiji
Published: April 2023

PDF file, 315K, Supplementary Figure S5 Relative body weight of mice during treatment with WZ4002 and/or E7050.
Supplementary Figure 1 from Ganetespib, a Unique Triazolone-Containing Hsp90 Inhibitor, Exhibits Potent Antitumor Activity and a Superior Safety Profile for Cancer Therapy
Authors: Ying Weiwen , Du Zhenjian , Sun Lijun , Foley Kevin P. , Proia David A. , Blackman Ronald K. , Zhou Dan , Inoue Takayo , Tatsuta Noriaki , Sang Jim , Ye Shuxia , Acquaviva Jamie , Ogawa Luisa Shin , Wada Yumiko , Barsoum James , Koya Keizo
Published: April 2023

PDF file - 280K
Supplementary Figure 3 from Combined Therapy with Mutant-Selective EGFR Inhibitor and Met Kinase Inhibitor for Overcoming Erlotinib Resistance in EGFR-Mutant Lung Cancer
Authors: Nakagawa Takayuki , Takeuchi Shinji , Yamada Tadaaki , Nanjo Shigeki , Ishikawa Daisuke , Sano Takako , Kita Kenji , Nakamura Takahiro , Matsumoto Kunio , Suda Kenichi , Mitsudomi Tetsuya , Sekido Yoshitaka , Uenaka Toshimitsu , Yano Seiji
Published: April 2023

PDF file, 181K, Supplementary Figure S3 Sustained inhibition of Akt and Erk phosphorylation by combining WZ4002 and E7050.
Supplementary Figure Legend from Preclinical Analysis of the γ-Secretase Inhibitor PF-03084014 in Combination with Glucocorticoids in T-cell Acute Lymphoblastic Leukemia
Authors: Samon Jeremy B. , Castillo-Martin Mireia , Hadler Michael , Ambesi-Impiobato Alberto , Paietta Elisabeth , Racevskis Janis , Wiernik Peter H. , Rowe Jacob M. , Jakubczak John , Randolph Sophia , Cordon-Cardo Carlos , Ferrando Adolfo A.
Published: April 2023

PDF file, 69KB.
Supplementary Figure 2 from Combined Therapy with Mutant-Selective EGFR Inhibitor and Met Kinase Inhibitor for Overcoming Erlotinib Resistance in EGFR-Mutant Lung Cancer
Authors: Nakagawa Takayuki , Takeuchi Shinji , Yamada Tadaaki , Nanjo Shigeki , Ishikawa Daisuke , Sano Takako , Kita Kenji , Nakamura Takahiro , Matsumoto Kunio , Suda Kenichi , Mitsudomi Tetsuya , Sekido Yoshitaka , Uenaka Toshimitsu , Yano Seiji
Published: April 2023

PDF file, 115K, Supplementary Figure S2 E7050 inhibits tumor cell motility induced by HGF overexpression.
Supplementary Figure 2 from Preclinical Analysis of the γ-Secretase Inhibitor PF-03084014 in Combination with Glucocorticoids in T-cell Acute Lymphoblastic Leukemia
Authors: Samon Jeremy B. , Castillo-Martin Mireia , Hadler Michael , Ambesi-Impiobato Alberto , Paietta Elisabeth , Racevskis Janis , Wiernik Peter H. , Rowe Jacob M. , Jakubczak John , Randolph Sophia , Cordon-Cardo Carlos , Ferrando Adolfo A.
Published: April 2023

PDF file, 567KB, Absence of synergistic interaction between PF-03084014 and glucocorticoids in gamma-secretase inhibitor- and glucocorticoid-resistant cell lines.
Supplementary Figure 1 from Preclinical Analysis of the γ-Secretase Inhibitor PF-03084014 in Combination with Glucocorticoids in T-cell Acute Lymphoblastic Leukemia
Authors: Samon Jeremy B. , Castillo-Martin Mireia , Hadler Michael , Ambesi-Impiobato Alberto , Paietta Elisabeth , Racevskis Janis , Wiernik Peter H. , Rowe Jacob M. , Jakubczak John , Randolph Sophia , Cordon-Cardo Carlos , Ferrando Adolfo A.
Published: April 2023

PDF file, 252KB, PF-03084014 reverses glucocorticoid resistance in T-ALL cell lines.
Supplementary Figure 2 from CBS9106-Induced CRM1 Degradation Is Mediated by Cullin Ring Ligase Activity and the Neddylation Pathway
Authors: Saito Naoya , Sakakibara Keiichi , Sato Takuji , Friedman Jonathan M. , Kufe Donald W. , VonHoff Daniel D. , Kawabe Takumi
Published: April 2023

Supplementary Figure 2: MLN4924 (50 nM) increases subG1 and DNA content. HCT116 cells are treated with increasing concentrations of MLN4924 (0, 1, 10, or 50 nM) for 72 hours. The population is measured by flow cytometry after staining with propidium iodide (n = 3). Data are expressed as the mean {plus minus} SD.
Supplementary Figure 1 from CBS9106-Induced CRM1 Degradation Is Mediated by Cullin Ring Ligase Activity and the Neddylation Pathway
Authors: Saito Naoya , Sakakibara Keiichi , Sato Takuji , Friedman Jonathan M. , Kufe Donald W. , VonHoff Daniel D. , Kawabe Takumi
Published: April 2023

Supplementary Figure 1: CBS9106 reduces CRM1 protein levels through neddylation -mediated degradation in MM.1S cells. (A) MM.1S cells are treated with CBS9106 (50 nM) and/or MLN4924 (100 nM) for indicated period (0-8 hours). (B) Cells are treated with increasing concentrations of MLN4924 (0, 10, 20, 50, or 100 nM) and/or CBS9106 (50 nM) for 24 hours. (A, B) Protein levels of CRM1, CyclinB1, CulNEDD8, p53, PARP, p27, CDT1, and beta-actin are determined by western blot analysis. The measured band density was normalized relative to that of the control sample, with the control value set to 1. MM.1S cells was kindly provided by Dr. H. Yasui (University of tokyo, Tokyo, Japan). Cleaved PARP:clPARP.
Supplementary Figures S1-S6 from Functional Genetic Screen Identifies Increased Sensitivity to WEE1 Inhibition in Cells with Defects in Fanconi Anemia and HR Pathways
Authors: Aarts Marieke , Bajrami Ilirjana , Herrera-Abreu Maria T. , Elliott Richard , Brough Rachel , Ashworth Alan , Lord Christopher J. , Turner Nicholas C.
Published: April 2023

Figure S1: Hit validation of siRNA screen for determinants of WEE1 inhibitor sensitivity. Figure S2: WEE1 inhibition by MK-1775 induces replication stress without DSBs and is dependent on CDK1/2 activity. Figure S3: Dual inhibition of WEE1 and MYT1 by PD0166285 induces premature mitosis. Figure S4: Increased sensitivity to WEE1 inhibition in FANCM- or BRIP1-depleted cells is caused by replication stress and unscheduled mitosis. Figure S5: Nucleoside supplementation defers the onset of replication stress and unscheduled mitosis triggered by WEE1 inhibition in cells with FA defects. Figure S6: Co-depletion of MRE11, but not MUS81 or SLX4, partially rescued the replication stress and unscheduled mitosis induced by WEE1 inhibition in FANCM- and BRIP1-depleted cells.
Supplementary Figure 1 from Apoptotic Circulating Tumor Cells in Early and Metastatic Breast Cancer Patients
Authors: Kallergi Galatea , Konstantinidis Georgios , Markomanolaki Harris , Papadaki Maria A. , Mavroudis Dimitris , Stournaras Christos , Georgoulias Vassilis , Agelaki Sofia
Published: April 2023

PDF file - 46K, Characterization of apoptotic and proliferative CTCs prior to and after adjuvant treatment.
Supplementary Figure Legends, Tables 1 - 2 from Therapeutic Inhibition of Jak Activity Inhibits Progression of Gastrointestinal Tumors in Mice
Authors: Stuart Emma , Buchert Michael , Putoczki Tracy , Thiem Stefan , Farid Ryan , Elzer Joachim , Huszar Dennis , Waring Paul M. , Phesse Toby J. , Ernst Matthias
Published: April 2023

PDF file - 141K, Table S1. Primers used for quantitative PCR analysis. Table S2. Antibodies (all diluted 1:1000) used for immunohistochemistry and Western Blot analysis.
Supplementary Methods, Figures 1 - 7 from Hrk Mediates 2-Methoxyestradiol–Induced Mitochondrial Apoptotic Signaling in Prostate Cancer Cells
Authors: Chang Inik , Majid Shahana , Saini Sharanjot , Zaman Mohd S. , Yamamura Soichiro , Chiyomaru Takeshi , Shahryari Varahram , Fukuhara Shinichiro , Deng Guoren , Dahiya Rajvir , Tanaka Yuichiro
Published: April 2023

PDF file - 321K, Figure S1. Induction of BH3-only protein family members by 2-ME in prostate cancer cells. Figure S2. Hrk knockdown prevents 2-ME-mediated cell death in time-dependent manner. Figure S3. Mitochondrial localization of Hrk. Figure S4. No change in total cell number after 2-ME treatment. Figure S5. Bax is not involved in 2-ME-mediated apoptotic cell death. Figure S6. Endogenous Bak interacts with Bcl-xL but not with Bcl-2 in prostate cancer cells. Figure S7. Hrk requires the BH3 domain for pro-apoptotic function.
Supplemental Figure 3 from CD30 Downregulation, MMAE Resistance, and MDR1 Upregulation Are All Associated with Resistance to Brentuximab Vedotin
Authors: Chen Robert , Hou Jessie , Newman Edward , Kim Young , Donohue Cecile , Liu Xueli , Thomas Sandra H. , Forman Stephen J. , Kane Susan E.
Published: April 2023

Supplemental Figure 3. Rhodamine Efflux Assay.
Supplementary Figures S1 - S8 and Tables S1 - S2 from In Vitro and In Vivo Interactions between the HDAC6 Inhibitor Ricolinostat (ACY1215) and the Irreversible Proteasome Inhibitor Carfilzomib in Non-Hodgkin Lymphoma Cells
Authors: Dasmahapatra Girija , Patel Hiral , Friedberg Johnathan , Quayle Steven N. , Jones Simon S. , Grant Steven
Published: April 2023

Supplementary Figures and Tables. Fig 1: Synergistic interactions between CFZ and ACY1215 lead to induction of apoptosis in a time-dependent manner. Fig 2: Knocking down HDAC6 expression by shRNA or pharmacologic inhibition by ACY1215 or Tubastatin A potentiates proteasome inhibitor lethality. Fig 3: Combined CFZ/ACY1215 exposure activates stress pathways and increases DNA damage in SUDHL16 cell. Fig 4: Pre-treatment of cells with pan-caspase inhibitor BOC does not protect JNK activation, induction of DNA damage and inactivation of ERK. Fig 5: Knocking down HDAC6 expression by shRNA recapitulate signaling events when treated with ACY1215 alone similar to combined treatment of CFZ+ ACY1215 to untransfected cells. Fig 6: CFZ and ACY1215 interact synergistically in bortezomib-resistant DLBCL and MCL cells. Fig 7: Constitutive MEK/ERK phosphorylation does not protect SUDHL4 cells from the ACY1215+CFZ regimen. Fig 8: Knocking down of Histone1.2 circumvent the lethality of ACY1215+CFZ drug regimen in U2932 cells. Sup Table 1: Addition of ACY1215 to CFZ does not enhance inhibition of chymotryptic activity in DLBCL cells. Sup Table 2: Combined ACY1215t/CFZ exposure leads to G2M arrest of DLBCL cells.
Supplementary Figure 2 from Smac Mimetics in Combination with TRAIL Selectively Target Cancer Stem Cells in Nasopharyngeal Carcinoma
Authors: Wu Man-si , Wang Guang-feng , Zhao Zhi-qiang , Liang Yi , Wang Heng-bang , Wu Miao-yi , Min Ping , Chen Li-zhen , Feng Qi-sheng , Bei Jin-xin , Zeng Yi-xin , Yang Dajun
Published: April 2023

PDF file - 3401K, Figure S2. Photographs of colony and sphere formation assay of treated S18 cells.
Supplementary Figure Legend, Table 1 from Nonclinical Evaluation of the Serum Pharmacodynamic Biomarkers HGF and Shed MET following Dosing with the Anti-MET Monovalent Monoclonal Antibody Onartuzumab
Authors: Mai Elaine , Zheng Zhong , Chen Youjun , Peng Jing , Severin Christophe , Filvaroff Ellen , Romero Mally , Mallet William , Kaur Surinder , Gelzleichter Thomas , Nijem Ihsan , Merchant Mark , Young Judy C.
Published: April 2023

PDF file - 76K, Supplemental Table 1: Oligonucleotide sequences.
Supplementary Figure 1 from Nonclinical Evaluation of the Serum Pharmacodynamic Biomarkers HGF and Shed MET following Dosing with the Anti-MET Monovalent Monoclonal Antibody Onartuzumab
Authors: Mai Elaine , Zheng Zhong , Chen Youjun , Peng Jing , Severin Christophe , Filvaroff Ellen , Romero Mally , Mallet William , Kaur Surinder , Gelzleichter Thomas , Nijem Ihsan , Merchant Mark , Young Judy C.
Published: April 2023

PDF file - 21K, Supplemental Figure 1. Human sMET (A) and HGF (B) levels in human plasma samples from a panel of 20 renal cell carcinoma patients and 15 normal donors were measured using the MET ECLA (A) and HGF ELISA (B), respectively.
Supplementary Figure S5 from Transcriptomic and Protein Expression Analysis Reveals Clinicopathological Significance of Bloom Syndrome Helicase (BLM) in Breast Cancer
Authors: Arora Arvind , Abdel-Fatah Tarek M.A. , Agarwal Devika , Doherty Rachel , Moseley Paul M. , Aleskandarany Mohammed A. , Green Andrew R. , Ball Graham , Alshareeda Alaa T. , Rakha Emad A. , Chan Stephen Y.T. , Ellis Ian O. , Madhusudan Srinivasan
Published: April 2023

BLM-Rad51 co-expression and survival in ER+ breast cancers.
Data Supplement from NEO212, Temozolomide Conjugated to Perillyl Alcohol, Is a Novel Drug for Effective Treatment of a Broad Range of Temozolomide-Resistant Gliomas
Authors: Cho Hee-Yeon , Wang Weijun , Jhaveri Niyati , Lee David Jungpa , Sharma Natasha , Dubeau Louis , Schönthal Axel H. , Hofman Florence M. , Chen Thomas C.
Published: April 2023

Supplementary Figure 3. Cytotoxic effects of NEO212 on primary glioma cells
Supplementary Figure S3 from Transcriptomic and Protein Expression Analysis Reveals Clinicopathological Significance of Bloom Syndrome Helicase (BLM) in Breast Cancer
Authors: Arora Arvind , Abdel-Fatah Tarek M.A. , Agarwal Devika , Doherty Rachel , Moseley Paul M. , Aleskandarany Mohammed A. , Green Andrew R. , Ball Graham , Alshareeda Alaa T. , Rakha Emad A. , Chan Stephen Y.T. , Ellis Ian O. , Madhusudan Srinivasan
Published: April 2023

BLM protein expression and survival.
Supplementary Figure S1 from Transcriptomic and Protein Expression Analysis Reveals Clinicopathological Significance of Bloom Syndrome Helicase (BLM) in Breast Cancer
Authors: Arora Arvind , Abdel-Fatah Tarek M.A. , Agarwal Devika , Doherty Rachel , Moseley Paul M. , Aleskandarany Mohammed A. , Green Andrew R. , Ball Graham , Alshareeda Alaa T. , Rakha Emad A. , Chan Stephen Y.T. , Ellis Ian O. , Madhusudan Srinivasan
Published: April 2023

BLM m RNA and breast cancer (external validation cohort).
Supplementary Figure 1 from Vinblastine Rapidly Induces NOXA and Acutely Sensitizes Primary Chronic Lymphocytic Leukemia Cells to ABT-737
Authors: Bates Darcy J.P. , Danilov Alexey V. , Lowrey Christopher H. , Eastman Alan
Published: April 2023

PDF file - 62K, Figure S1. JNK is not required for apoptosis induced by the combination of vinblastine plus ABT-737.
Supplementary Figure 2 from Novel Target for Peptide-Based Imaging and Treatment of Brain Tumors
Authors: Hyvönen Maija , Enbäck Juulia , Huhtala Tuulia , Lammi Johanna , Sihto Harri , Weisell Janne , Joensuu Heikki , Rosenthal-Aizman Katri , El-Andaloussi Samir , Langel Ulo , Närvänen Ale , Bergers Gabriele , Laakkonen Pirjo
Published: April 2023

PDF - 8691K, MDGI expression in glioma xenografts.
Supplementary Tables 1 and 2 and Supplementary Figures 1 through 7 from Evaluation of Apoptosis Induction by Concomitant Inhibition of MEK, mTOR, and Bcl-2 in Human Acute Myelogenous Leukemia Cells
Authors: Zhang Weiguo , Ruvolo Vivian R. , Gao Chen , Zhou Liran , Bornmann William , Tsao Twee , Schober Wendy D. , Smith Paul , Guichard Sylvie , Konopleva Marina , Andreeff Michael
Published: April 2023

PDF - 495K, Supplementary Table 1: Gene Alterations in AML Cell Lines used in This Study Supplementary table 52:Gene alterations and cytogenetic information on 10 periphoral blood or bone marrow samples obtained from AML patients Fig. S1. Molecular structures of drugs used in this study. Fig. S2. The Chou-Talalay method Chou et al. Cancer Res. 2010; 70: 440-446 was used to determine combination indices (CIs) in AML cell lines treated with combination of AZD8055 and selumetinib for 48 hours. Fig. S3. OCI/AML3 cells were pretreated with proteasome inhibitors bortezemib (0.01 micromol/L) or MG132 (0.5 micromol/L) for 2 hours following by combination of AZD8055 (0.4 micromol/L) and selumetinib (0.2 micromol/L) for additional 48 hours. The apoptosis induction was measured using flow cytometry. Fig. S4. U937 cells were electroporated with Bim siRNA or scrambled siRNA for 24 hours, treated with AZD8055 (0.4 micromol/L) and/or selumetinib (0.2 micromol/L) for 48 hours, and examined for apoptosis induction. Inset: knockdown of basal level of Bim protein expression. Fig. S5. AML cells were treated with indicated doses of selumetinib for 48 hours and apoptosis induction was determined using flow cytometry by measuring percentage of Annexin V positivity. Fig. S6. AML cells were treated with indicated doses of AZD8055 for 48 hours and apoptosis induction was determined using flow cytometry by measuring percentage of Annexin V positivity. Fig. S7. OCI/AMl3_shGFP and OCI/AMl3_shMcl-1 AML cells were treated with indicated doses of ABT-737 for 48 hours and apoptosis induction was determined using flow cytometry by measuring Annexin Vneg/PIneg population.
Supplementary Figure Legend from Comparing Histone Deacetylase Inhibitor Responses in Genetically Engineered Mouse Lung Cancer Models and a Window of Opportunity Trial in Patients with Lung Cancer
Authors: Ma Tian , Galimberti Fabrizio , Erkmen Cherie P. , Memoli Vincent , Chinyengetere Fadzai , Sempere Lorenzo , Beumer Jan H. , Anyang Bean N. , Nugent William , Johnstone David , Tsongalis Gregory J. , Kurie Jonathan M. , Li Hua , DiRenzo James , Guo Yongli , Freemantle Sarah J. , Dragnev Konstantin H. , Dmitrovsky Ethan
Published: April 2023

PDF file - 59K
Supplementary Figure 2 from Comparing Histone Deacetylase Inhibitor Responses in Genetically Engineered Mouse Lung Cancer Models and a Window of Opportunity Trial in Patients with Lung Cancer
Authors: Ma Tian , Galimberti Fabrizio , Erkmen Cherie P. , Memoli Vincent , Chinyengetere Fadzai , Sempere Lorenzo , Beumer Jan H. , Anyang Bean N. , Nugent William , Johnstone David , Tsongalis Gregory J. , Kurie Jonathan M. , Li Hua , DiRenzo James , Guo Yongli , Freemantle Sarah J. , Dragnev Konstantin H. , Dmitrovsky Ethan
Published: April 2023

PDF file - 1690K, Supplemental Fig. 2: Pharmacodynamic effects of vorinostat in (A) murine ED-1 lung cancer cells and (B) human HOP62 lung cancer cells. Vorinostat dose-dependent effects were investigated by immunoblot analyses for Bcl-2 family members (Bcl-2, Mcl-1, Bax and Bim); DNA damage response proteins (γH2AX and Chk1); the epithelial-mesenchymal transition (EMT) biomarker E-cadherin; and other growth regulatory proteins (c-raf, p-Akt, Akt, p21, and acetyl-α tubulin).
Supplementary Figure 6 from BCL-2 Hypermethylation Is a Potential Biomarker of Sensitivity to Antimitotic Chemotherapy in Endocrine-Resistant Breast Cancer
Authors: Stone Andrew , Cowley Mark J. , Valdes-Mora Fatima , McCloy Rachael A. , Sergio C. Marcelo , Gallego-Ortega David , Caldon C. Elizabeth , Ormandy Christopher J. , Biankin Andrew V. , Gee Julia M.W. , Nicholson Robert I. , Print Cristin G. , Clark Susan J. , Musgrove Elizabeth A.
Published: April 2023

PDF - 80KB, The effect of BI2536 in endocrine-sensitive and endocrine-resistant breast cancer cells.
Supplementary Materials and Methods, Figures 1 - 9, Tables 1 - 5 from Monensin Inhibits Canonical Wnt Signaling in Human Colorectal Cancer Cells and Suppresses Tumor Growth in Multiple Intestinal Neoplasia Mice
Authors: Tumova Lucie , Pombinho Antonio R. , Vojtechova Martina , Stancikova Jitka , Gradl Dietmar , Krausova Michaela , Sloncova Eva , Horazna Monika , Kriz Vitezslav , Machonova Olga , Jindrich Jindrich , Zdrahal Zbynek , Bartunek Petr , Korinek Vladimir
Published: April 2023

PDF file - 515KB, Supplementary Materials and Methods. Supplementary Figure S1. Densitometric analysis of western blots shown in Figs. 2D (A), 3C (B) and 4D (C). Supplementary Figure S2. Monensin suppresses Wnt signaling activated by TALEN-induced disruption of the APC gene. Supplementary Figure S3. Monensin does not interfere with Dvl phoshorylation. Supplementary Figure S4. The inhibitory effect of monensin on Wnt signaling is not restricted to the vesicular acidity blockade. Supplementary Figure S5. Monensin inhibits aberrant Wnt signaling in CRC cells COLO320 and LS174T. Supplementary Figure S6. ROS concentration is not increased by monensin. Supplementary Figure S7. Membranous localization of beta-catenin in HCT116 cells. Supplementary Figure S8. Monensin does not inhibit beta-catenin acetylation. Supplementary Figure S9. Monensin does not change the fraction of proliferating cells in intestinal tumors. Supplementary Table S1. Sequences of primers used for qRT-PCR analyses. Supplementary Table S2. Monensin does not inhibit enzymatic activity of any of the tested protein kinases. Supplementary Table S3. qRT-PCR analysis of the TCF/beta-catenin target gene expression in CRC cells. Supplementary Table S4. Cell cycle analysis of SW480 and HCT116 cells. Supplementary Table S5. Analysis of phosphorylated amino acid residues in beta-catenin.
Supplementary Figure 5 from BCL-2 Hypermethylation Is a Potential Biomarker of Sensitivity to Antimitotic Chemotherapy in Endocrine-Resistant Breast Cancer
Authors: Stone Andrew , Cowley Mark J. , Valdes-Mora Fatima , McCloy Rachael A. , Sergio C. Marcelo , Gallego-Ortega David , Caldon C. Elizabeth , Ormandy Christopher J. , Biankin Andrew V. , Gee Julia M.W. , Nicholson Robert I. , Print Cristin G. , Clark Susan J. , Musgrove Elizabeth A.
Published: April 2023

PDF - 221KB, A. Plk1 Expression vs relapse-free survival in endocrine treated ER-positive breast cancer patients (n=287). B. Correlative analysis of ER, BCL-2 and PLK1 gene expression in TCGA breast cohort (n=774).
Supplementary Figure 4 from BCL-2 Hypermethylation Is a Potential Biomarker of Sensitivity to Antimitotic Chemotherapy in Endocrine-Resistant Breast Cancer
Authors: Stone Andrew , Cowley Mark J. , Valdes-Mora Fatima , McCloy Rachael A. , Sergio C. Marcelo , Gallego-Ortega David , Caldon C. Elizabeth , Ormandy Christopher J. , Biankin Andrew V. , Gee Julia M.W. , Nicholson Robert I. , Print Cristin G. , Clark Susan J. , Musgrove Elizabeth A.
Published: April 2023

PDF - 4365KB, BCL-2 Methylation vs disease free survival.
Supplementary Table 4 from Coleusin Factor, a Novel Anticancer Diterpenoid, Inhibits Osteosarcoma Growth by Inducing Bone Morphogenetic Protein-2–Dependent Differentiation
Authors: Geng Shuo , Sun Bo , Lu Ran , Wang Jingze
Published: April 2023

PDF - 64K, Cell cycle distribution of U-2 OS cells.
Supplementary Figure 1 from BCL-2 Hypermethylation Is a Potential Biomarker of Sensitivity to Antimitotic Chemotherapy in Endocrine-Resistant Breast Cancer
Authors: Stone Andrew , Cowley Mark J. , Valdes-Mora Fatima , McCloy Rachael A. , Sergio C. Marcelo , Gallego-Ortega David , Caldon C. Elizabeth , Ormandy Christopher J. , Biankin Andrew V. , Gee Julia M.W. , Nicholson Robert I. , Print Cristin G. , Clark Susan J. , Musgrove Elizabeth A.
Published: April 2023

PDF - 289KB, BCL-2 450K Methylation array probes (n=42).
Supplementary Table 1 from Coleusin Factor, a Novel Anticancer Diterpenoid, Inhibits Osteosarcoma Growth by Inducing Bone Morphogenetic Protein-2–Dependent Differentiation
Authors: Geng Shuo , Sun Bo , Lu Ran , Wang Jingze
Published: April 2023

PDF - 60K, Primers used for RT-PCR.
Supplementary Materials from A Pragmatic Definition of Therapeutic Synergy Suitable for Clinically Relevant In Vitro Multicompound Analyses
Authors: Kashif Muhammad , Andersson Claes , Åberg Magnus , Nygren Peter , Sjöblom Tobias , Hammerling Ulf , Larsson Rolf , Gustafsson Mats G.
Published: April 2023

PDF - 105K, This supplement contains three parts. The first presents a motivation/derivation of the cell proliferation model used in the main text. The second gives the theroetical details about the omnibus statistical test used in the main text. The third part presents an extended discussion regarding two topics breifly mentioned at the end of the main text.
Supplementary Figure 2 from Coleusin Factor, a Novel Anticancer Diterpenoid, Inhibits Osteosarcoma Growth by Inducing Bone Morphogenetic Protein-2–Dependent Differentiation
Authors: Geng Shuo , Sun Bo , Lu Ran , Wang Jingze
Published: April 2023

PDF - 166K, BMP-2 is critical for CF-mediated differentiation of U-2 OS cells.
Supplementary Figures 1 - 4 from Endothelial Cells Enhance Prostate Cancer Metastasis via IL-6→Androgen Receptor→TGF-β→MMP-9 Signals
Authors: Wang Xiaohai , Lee Soo Ok , Xia Shujie , Jiang Qi , Luo Jie , Li Lei , Yeh Shuyuan , Chang Chawnshang
Published: April 2023

PDF file - 267K, Fig. s1. HMECs induce the PCa cells invasion in vitro. Fig. s2. ECs down-regulated AR signaling in PCa cells. Fig. s3. Cytokines/chemokines level changes in ECs upon PCa cells co-culture. Fig. s4. EMT markers expressions changes in PCa cells upon ECs co-culture.
Supplementary Table 3 from Contribution of ATM and ATR to the Resistance of Glioblastoma and Malignant Melanoma Cells to the Methylating Anticancer Drug Temozolomide
Authors: Eich Marcus , Roos Wynand Paul , Nikolova Teodora , Kaina Bernd
Published: April 2023

PDF file - 78 KB, Apoptosis and necrosis rates of cell death data for glioblastoma and malignant melanoma cells
Supplementary Figure 2 from MiR-134/487b/655 Cluster Regulates TGF-β–Induced Epithelial–Mesenchymal Transition and Drug Resistance to Gefitinib by Targeting MAGI2 in Lung Adenocarcinoma Cells
Authors: Kitamura Kazuhiro , Seike Masahiro , Okano Tetsuya , Matsuda Kuniko , Miyanaga Akihiko , Mizutani Hideaki , Noro Rintaro , Minegishi Yuji , Kubota Kaoru , Gemma Akihiko
Published: April 2023

PDF file - 117K, Supplementary Figure S2: Efficiency of transfection with miR134/487b precursors or miR-134/487 inhibitors.
Supplementary Figure 2 from Combination of Imatinib with CXCR4 Antagonist BKT140 Overcomes the Protective Effect of Stroma and Targets CML In Vitro and In Vivo
Authors: Beider Katia , Darash-Yahana Merav , Blaier Orly , Koren-Michowitz Maya , Abraham Michal , Wald Hanna , Wald Ori , Galun Eithan , Eizenberg Orly , Peled Amnon , Nagler Arnon
Published: April 2023

PDF - 32K, BKT140 structure.
Supplementary Table 1 from Preclinical Evaluation of the WEE1 Inhibitor MK-1775 as Single-Agent Anticancer Therapy
Authors: Guertin Amy D. , Li Jing , Liu Yaping , Hurd Melissa S. , Schuller Alwin G. , Long Brian , Hirsch Heather A. , Feldman Igor , Benita Yair , Toniatti Carlo , Zawel Leigh , Fawell Stephen E. , Gilliland D. Gary , Shumway Stuart D.
Published: April 2023

XLSX file - 155K, Proliferation assay EC50 results for MK-1775 in diverse tumor cell lines.
Supplementary Table S3 from Triptolide Induces the Expression of miR-142-3p: A Negative Regulator of Heat Shock Protein 70 and Pancreatic Cancer Cell Proliferation
Authors: MacKenzie Tiffany N. , Mujumdar Nameeta , Banerjee Sulagna , Sangwan Veena , Sarver Aaron , Vickers Selwyn , Subramanian Subbaya , Saluja Ashok K.
Published: April 2023

Supplementary Table S3 - PDF file 39K, Computational prediction of miR-142-3p target mRNA
Supplementary Table 1 from GSK3 Inhibitors Regulate MYCN mRNA Levels and Reduce Neuroblastoma Cell Viability through Multiple Mechanisms, Including p53 and Wnt Signaling
Authors: Duffy David J. , Krstic Aleksandar , Schwarzl Thomas , Higgins Desmond G. , Kolch Walter
Published: April 2023

PDF - 219K, Table S1. CAS (Chemical Abstracts Service) numbers, molecular formulas, structures and references for each of the compounds used in the study.
Supplementary Figure 4 from GSK3 Inhibitors Regulate MYCN mRNA Levels and Reduce Neuroblastoma Cell Viability through Multiple Mechanisms, Including p53 and Wnt Signaling
Authors: Duffy David J. , Krstic Aleksandar , Schwarzl Thomas , Higgins Desmond G. , Kolch Walter
Published: April 2023

PDF - 78K, Figure S4. Additional PFTalpha and GSK3 inhibitor co-treatment viability data. A. Attempted p53 mediated rescue of GSK3 inhibitor cell death phenotype across three cell lines as measured by MTS viability assay after 24h and 48h of treatment. Only BIO treatment in IMR32 and KCNR showed partial rescue upon PFTalpha co-treatment.
Supplementary Figure 3 from GSK3 Inhibitors Regulate MYCN mRNA Levels and Reduce Neuroblastoma Cell Viability through Multiple Mechanisms, Including p53 and Wnt Signaling
Authors: Duffy David J. , Krstic Aleksandar , Schwarzl Thomas , Higgins Desmond G. , Kolch Walter
Published: April 2023

PDF - 259K, Figure S3. Additional p53 and neuroblastoma prognostic markers overlap data. A. p53 signalling pathway schematic with LiCl differentially regulated genes overlaid, key as in image and as described in Fig. 5B. B. Overlap between IPA predicted upstream regulators from inhibitor mRNA-seq (top 110) and a 157 neuroblastoma risk stratification gene signature (all 31), image generated using Venny.
Supplementary Figure Legend from Glioblastoma Cells Containing Mutations in the Cohesin Component STAG2 Are Sensitive to PARP Inhibition
Authors: Bailey Melanie L. , O'Neil Nigel J. , van Pel Derek M. , Solomon David A. , Waldman Todd , Hieter Philip
Published: April 2023

PDF file - 76K
Supplementary Figure 7 from Glioblastoma Cells Containing Mutations in the Cohesin Component STAG2 Are Sensitive to PARP Inhibition
Authors: Bailey Melanie L. , O'Neil Nigel J. , van Pel Derek M. , Solomon David A. , Waldman Todd , Hieter Philip
Published: April 2023

PDF file - 53K, Supp. Fig. 7- A) Effect of camptothecin (CPT) on H4 STAG2-mutated and KI cell lines. B) 42MGBA STAG2-mutated and KI cell lines treated with a combination of CPT and olaparib. Cell numbers were determined by nuclei-counting.
Supplementary Figure 6 from Glioblastoma Cells Containing Mutations in the Cohesin Component STAG2 Are Sensitive to PARP Inhibition
Authors: Bailey Melanie L. , O'Neil Nigel J. , van Pel Derek M. , Solomon David A. , Waldman Todd , Hieter Philip
Published: April 2023

PDF file - 157K, Supp. Fig. 6- Incidence of A) micronuclei (MN), B) chromatin bridges (CB) and C) fragmented nuclei (FN) and in 42MGBA cell lines either untreated or treated with olaparib for four days. Graphs represent cell counts from three independent experiments. D) Presence of 53BP1 foci in paired 42MGBA cell lines untreated and treated with olaparib for four days. Error bars in D) are 95% confidence intervals.
Supplementary Figure 4 from Glioblastoma Cells Containing Mutations in the Cohesin Component STAG2 Are Sensitive to PARP Inhibition
Authors: Bailey Melanie L. , O'Neil Nigel J. , van Pel Derek M. , Solomon David A. , Waldman Todd , Hieter Philip
Published: April 2023

PDF file - 404K, Supp. Fig. 4- Representative images of H4 and H4 STAG2 KI DAPI-stained nuclei treated with increasing concentrations of olaparib for three days. Examples of micronuclei (MN), fragmented nuclei (FN) and chromatin bridges (CB) are shown.
Supplementary Figure 3 from Glioblastoma Cells Containing Mutations in the Cohesin Component STAG2 Are Sensitive to PARP Inhibition
Authors: Bailey Melanie L. , O'Neil Nigel J. , van Pel Derek M. , Solomon David A. , Waldman Todd , Hieter Philip
Published: April 2023

PDF file - 56K, Supp. Fig. 3- A) Propidium iodide-stained flow cytometry profiles of 42MGBA cell lines untreated and treated with olaparib. B) Cell cycle distribution of 42MGBA cell populations from three independent experiments.
Supplementary Methods, Figure Legends from A Small Molecule That Binds and Inhibits the ETV1 Transcription Factor Oncoprotein
Authors: Pop Marius S. , Stransky Nicolas , Garvie Colin W. , Theurillat Jean-Philippe , Hartman Emily C. , Lewis Timothy A. , Zhong Cheng , Culyba Elizabeth K. , Lin Fallon , Daniels Douglas S. , Pagliarini Raymond , Ronco Lucienne , Koehler Angela N. , Garraway Levi A.
Published: April 2023

PDF file - 115K
Supplementary Figure Legends from Birinapant (TL32711), a Bivalent SMAC Mimetic, Targets TRAF2-Associated cIAPs, Abrogates TNF-Induced NF-κB Activation, and Is Active in Patient-Derived Xenograft Models
Authors: Benetatos Christopher A. , Mitsuuchi Yasuhiro , Burns Jennifer M. , Neiman Eric M. , Condon Stephen M. , Yu Guangyao , Seipel Martin E. , Kapoor Gurpreet S. , LaPorte Matthew G. , Rippin Susan R. , Deng Yijun , Hendi Mukta S. , Tirunahari Pavan K. , Lee Yu-Hua , Haimowitz Thomas , Alexander Matthew D. , Graham Martin A. , Weng David , Shi Yigong , McKinlay Mark A. , Chunduru Srinivas K.
Published: April 2023

PDF file - 73KB
Supplementary Materials and Methods, Supplementary Figure Legends, and Supplementary Tables 1 through 3 from EW-7197, a Novel ALK-5 Kinase Inhibitor, Potently Inhibits Breast to Lung Metastasis
Authors: Son Ji Yeon , Park So-Yeon , Kim Sol-Ji , Lee Seon Joo , Park Sang-A. , Kim Min-Jin , Kim Seung Won , Kim Dae-Kee , Nam Jeong-Seok , Sheen Yhun Yhong
Published: April 2023

PDF - 191K, Supplementary materials and methods and supplementary figure legends. Supplementary Table 1. Antibodies for Western blot analysis. Supplementary Table 2. Primers for qRT-PCR or RT-PCR. Supplementary Table 3. Radiometric protein kinase assay.
Supplementary Movie 6 from Tivantinib (ARQ 197) Exhibits Antitumor Activity by Directly Interacting with Tubulin and Overcomes ABC Transporter–Mediated Drug Resistance
Authors: Aoyama Aki , Katayama Ryohei , Oh-hara Tomoko , Sato Shigeo , Okuno Yasushi , Fujita Naoya
Published: April 2023

Vincristine treated (SK-MEL-28 Fucci).
Supplementary Figure 6 from EW-7197, a Novel ALK-5 Kinase Inhibitor, Potently Inhibits Breast to Lung Metastasis
Authors: Son Ji Yeon , Park So-Yeon , Kim Sol-Ji , Lee Seon Joo , Park Sang-A. , Kim Min-Jin , Kim Seung Won , Kim Dae-Kee , Nam Jeong-Seok , Sheen Yhun Yhong
Published: April 2023

PDF - 80K, (A, B) Breast cancer model #6 (described in the Material and Methods). (A) Inhibition of lung metastasis by EW-7197 was evaluated by analysis of luciferase activity in lungs of 4T1-luc orthotropic xenograft mice. Statistical significance was defined using one-way ANOVA with Dunnett's multiple comparison test. * indicates significance at p<0.05. (B) Effect of EW-7197 on primary tumor size. Data represent the mean (plus or minus) SE (n=15/group). Veh and EW indicate artificial gastric fluid and EW-7197, respectively.
Supplementary Movie 5 from Tivantinib (ARQ 197) Exhibits Antitumor Activity by Directly Interacting with Tubulin and Overcomes ABC Transporter–Mediated Drug Resistance
Authors: Aoyama Aki , Katayama Ryohei , Oh-hara Tomoko , Sato Shigeo , Okuno Yasushi , Fujita Naoya
Published: April 2023

Tivantinib treated (SK-MEL-28 Fucci).
Supplementary Figure 4 from EW-7197, a Novel ALK-5 Kinase Inhibitor, Potently Inhibits Breast to Lung Metastasis
Authors: Son Ji Yeon , Park So-Yeon , Kim Sol-Ji , Lee Seon Joo , Park Sang-A. , Kim Min-Jin , Kim Seung Won , Kim Dae-Kee , Nam Jeong-Seok , Sheen Yhun Yhong
Published: April 2023

PDF - 150K, Inhibitory effects of various ALK5 inhibitors on TGFbeta1-induced EMT in MCF10A cells. MCF10A cells were treated with TGFbeta1 (2 ng/ml) for 96 h in serum-reduced media (1% HI-HS) in the presence or absence of the indicated ALK5 inhibitors. Medium was replaced every other day. The protein levels of E-CADHERIN and N-CADHERIN were analyzed by western blotting as described in the Material and Methods. beta-ACTIN was used as endogenous control.
Supplementary Figure 3 from EW-7197, a Novel ALK-5 Kinase Inhibitor, Potently Inhibits Breast to Lung Metastasis
Authors: Son Ji Yeon , Park So-Yeon , Kim Sol-Ji , Lee Seon Joo , Park Sang-A. , Kim Min-Jin , Kim Seung Won , Kim Dae-Kee , Nam Jeong-Seok , Sheen Yhun Yhong
Published: April 2023

PDF - 430K, Inhibitory effects of various ALK5 inhibitors on TGF−beta1-induced EMT in MCF10A cells. MCF10A cells were treated with TGF−beta1 (2 ng/ml) for 96 h in serum-reduced media (1% heat inactivated-horse serum (HI-HS)) in the presence or absence of the indicated ALK5 inhibitors. Medium was replaced every other day. Cell morphology was observed by phase-contrast microscopy (total magnification: x 100, scale bar: 100 microm).
Supplementary Figure 2 from EW-7197, a Novel ALK-5 Kinase Inhibitor, Potently Inhibits Breast to Lung Metastasis
Authors: Son Ji Yeon , Park So-Yeon , Kim Sol-Ji , Lee Seon Joo , Park Sang-A. , Kim Min-Jin , Kim Seung Won , Kim Dae-Kee , Nam Jeong-Seok , Sheen Yhun Yhong
Published: April 2023

PDF - 202K, (A) Representative images of wound healing assay of MDA-MB-231 cells. Right after the wound was made on the MDA-MB-231 cell monolayer, the cells were treated with TGF-beta1 (2 ng/ml) with or without ALK5 inhibitors for 53 h. Total magnification was x 100. Scale bar indicates 100 microm. Veh, SB, and EW indicate vehicle, SB-505124, and EW-7197, respectively. (B, C) Effects of EW-7197 on cell cytotoxicity (described in the Supplementary Methods). 4T1 (B) and MCF10A (C) cells were treated with indicated concentrations of EW-7197 in 0.2% HI-FBS medium for 72 h. The cell viability was determined by SRB (Sulforhodamine B) assay (described in the Supplementary Methods). Data represent the mean (plus or minus) SD (n=3).
Supplementary Movie 1 from Tivantinib (ARQ 197) Exhibits Antitumor Activity by Directly Interacting with Tubulin and Overcomes ABC Transporter–Mediated Drug Resistance
Authors: Aoyama Aki , Katayama Ryohei , Oh-hara Tomoko , Sato Shigeo , Okuno Yasushi , Fujita Naoya
Published: April 2023

Control (EBC1-Fucci).
Supplementary Figure 1 from EW-7197, a Novel ALK-5 Kinase Inhibitor, Potently Inhibits Breast to Lung Metastasis
Authors: Son Ji Yeon , Park So-Yeon , Kim Sol-Ji , Lee Seon Joo , Park Sang-A. , Kim Min-Jin , Kim Seung Won , Kim Dae-Kee , Nam Jeong-Seok , Sheen Yhun Yhong
Published: April 2023

PDF - 120K, (A) Blockade of Smad2 phosphorylation by various ALK5 inhibitors. 4T1 cells starved in 0.2% HI-FBS medium for 24 h, and were treated with the indicated chemicals for 2 h with or without TGF-beta1 (2 ng/ml) in 0.2% HI-FBS medium. (B, C) Blockade of Smad2 phosphorylation by EW-7197. NMUMG (B) and MDA-MB-231 (C) cells were incubated with 0.2% HI-FBS medium for 24 h, and treated with TGF-beta1 (2 ng/ml) in the presence or absence of ALK5 inhibitors in 0.2% HI-FBS medium for 2 h. Lysates from the cells were analyzed by Western blotting. EW, SB, LY, IN indicate EW-7197, SB-505124, LY-2157299, and IN-1130, respectively.
Supplemental Figure 1; Table 1 from Circadian Clock Gene CRY2 Degradation Is Involved in Chemoresistance of Colorectal Cancer
Authors: Fang Lekun , Yang Zihuan , Zhou Junyi , Tung Jung-Yu , Hsiao Chwan-Deng , Wang Lei , Deng Yanhong , Wang Puning , Wang Jianping , Lee Mong-Hong
Published: April 2023

Supplemental Figure 1; Table 1. Supplemental Figure 1: Role of FBXW7 in drug sensitivity and cancer survival; Supplemental Table 1. Univariate and multivariate analysis of different prognostic parameters in 289 patients with colorectal cancer
Supplementary Figures 1 - 3, Tables 1 - 3 from Masitinib Antagonizes ATP-Binding Cassette Subfamily C Member 10–Mediated Paclitaxel Resistance: A Preclinical Study
Authors: Kathawala Rishil J. , Sodani Kamlesh , Chen Kang , Patel Atish , Abuznait Alaa H. , Anreddy Nagaraju , Sun Yue-Li , Kaddoumi Amal , Ashby Charles R. , Chen Zhe-Sheng
Published: April 2023

PDF file - 255K, Supplemental Figure 1. The expression of c-Kit and p-c-Kit protein in HEK293/pcDNA3.1 and HEK293/ABCC10 cell lines, respectively. Supplemental Figure 2. The effect of masitinib administration on HEK293/pcDNA3.1 tumor growth in vivo. Supplemental Figure 3. Model of masitinib-mediated sensitization of paclitaxel in tumor cells. Supplemental Table 1. Masitinib significantly sensitizes HEK293/ABCC10 cells to vinblastine and vincristine with no or minimal effect on HEK293/pcDNA3.1 cells. Supplemental Table 2. The effect of reversal drugs on the cytotoxicity of paclitaxel to HEK293/pcDNA3.1 and HEK293/ABCB1 cells. Supplemental Table 3. The effect of reversal drugs on the cytotoxicity of vincristine to HEK293/pcDNA3.1 and HEK293/ABCC1 cells.
Supplementary Figure 3 from Antitumor Activity of KW-2450 against Triple-Negative Breast Cancer by Inhibiting Aurora A and B Kinases
Authors: Kai Kazuharu , Kondo Kimie , Wang Xiaoping , Xie Xuemei , Pitner Mary K. , Reyes Monica E. , Torres-Adorno Angie M. , Masuda Hiroko , Hortobagyi Gabriel N. , Bartholomeusz Chandra , Saya Hideyuki , Tripathy Debu , Sen Subrata , Ueno Naoto T.
Published: April 2023

Knockdown of IGF-IR or InsR in TNBC cells.
Supplementary Figure 2 from Antitumor Activity of KW-2450 against Triple-Negative Breast Cancer by Inhibiting Aurora A and B Kinases
Authors: Kai Kazuharu , Kondo Kimie , Wang Xiaoping , Xie Xuemei , Pitner Mary K. , Reyes Monica E. , Torres-Adorno Angie M. , Masuda Hiroko , Hortobagyi Gabriel N. , Bartholomeusz Chandra , Saya Hideyuki , Tripathy Debu , Sen Subrata , Ueno Naoto T.
Published: April 2023

Inhibitory activity of KW-2450 against CD44+CD24- cancer stem cells in TNBC.
Supplementary Figure 1 from Antitumor Activity of KW-2450 against Triple-Negative Breast Cancer by Inhibiting Aurora A and B Kinases
Authors: Kai Kazuharu , Kondo Kimie , Wang Xiaoping , Xie Xuemei , Pitner Mary K. , Reyes Monica E. , Torres-Adorno Angie M. , Masuda Hiroko , Hortobagyi Gabriel N. , Bartholomeusz Chandra , Saya Hideyuki , Tripathy Debu , Sen Subrata , Ueno Naoto T.
Published: April 2023

Inhibitory activity of KW-2450 against p-IGF-IR in TNBC cells.
Supplementary Figure 2 from Moguntinones—New Selective Inhibitors for the Treatment of Human Colorectal Cancer
Authors: Maderer Annett , Plutizki Stanislav , Kramb Jan-Peter , Göpfert Katrin , Linnig Monika , Khillimberger Katrin , Ganser Christopher , Lauermann Eva , Dannhardt Gerd , Galle Peter R. , Moehler Markus
Published: April 2023

PDF file - 81K, Supplementary Figure 2. Effects of Moguntinon 19 and 13 on cell cycle and induction of apoptosis.
Supplementary Figure 1 from ERBB3/HER2 Signaling Promotes Resistance to EGFR Blockade in Head and Neck and Colorectal Cancer Models
Authors: Zhang Li , Castanaro Carla , Luan Bo , Yang Katie , Fan Liangfen , Fairhurst Jeanette L. , Rafique Ashique , Potocky Terra B. , Shan Jing , Delfino Frank J. , Shi Ergang , Huang Tammy , Martin Joel H. , Chen Gang , MacDonald Douglas , Rudge John S. , Thurston Gavin , Daly Christopher
Published: April 2023

PDF - 78K, Effect of REGN1400 and REGN955 on ligand-induced signaling by ERBB3 and EGFR, respectively.
Supplementary Figure 1 from Moguntinones—New Selective Inhibitors for the Treatment of Human Colorectal Cancer
Authors: Maderer Annett , Plutizki Stanislav , Kramb Jan-Peter , Göpfert Katrin , Linnig Monika , Khillimberger Katrin , Ganser Christopher , Lauermann Eva , Dannhardt Gerd , Galle Peter R. , Moehler Markus
Published: April 2023

PDF file - 66K, Supplementary Figure 1. Characterization of putative targets in human colon cancer cells.
Supplementary Figure 5 from Multivalent Scaffold Proteins as Superagonists of TRAIL Receptor 2–Induced Apoptosis
Authors: Swers Jeffery S. , Grinberg Luba , Wang Lin , Feng Hui , Lekstrom Kristen , Carrasco Rosa , Xiao Zhan , Inigo Ivan , Leow Ching Ching , Wu Herren , Tice David A. , Baca Manuel
Published: April 2023

PDF file - 148K, Supplementary Figure S5: G6T8 and G6T6 have similar cytotoxic activity on TRAIL-sensitive cell lines.
Supplemental Figures 1-4 from Small Molecule MYC Inhibitor Conjugated to Integrin-Targeted Nanoparticles Extends Survival in a Mouse Model of Disseminated Multiple Myeloma
Authors: Soodgupta Deepti , Pan Dipanjan , Cui Grace , Senpan Angana , Yang Xiaoxia , Lu Lan , Weilbaecher Katherine N. , Prochownik Edward V. , Lanza Gregory M. , Tomasson Michael H.
Published: April 2023

Supplemental Figures 1-4. Supplemental figure 1: Representative schematic of lipid encapsulated nanoparticle design. Supplemental figure 2: The pharmacokinetics nanoparticles Supplemental figure 3:Biodistribution of the Nanoparticles Supplemental figure 4: Kalwrij mice survival data
Supplementary Figure 3 from Multivalent Scaffold Proteins as Superagonists of TRAIL Receptor 2–Induced Apoptosis
Authors: Swers Jeffery S. , Grinberg Luba , Wang Lin , Feng Hui , Lekstrom Kristen , Carrasco Rosa , Xiao Zhan , Inigo Ivan , Leow Ching Ching , Wu Herren , Tice David A. , Baca Manuel
Published: April 2023

PDF file - 59K, Supplementary Figure S3: G6T8 is specific for human TRAILR2 and does not cross-react with other TRAIL receptors.
Supplementary Figure Legends from The HSP90 Inhibitor NVP-AUY922 Potently Inhibits Non–Small Cell Lung Cancer Growth
Authors: Garon Edward B. , Finn Richard S. , Hamidi Habib , Dering Judy , Pitts Sharon , Kamranpour Naeimeh , Desai Amrita J. , Hosmer Wylie , Ide Susan , Avsar Emin , Jensen Michael Rugaard , Quadt Cornelia , Liu Manway , Dubinett Steven M. , Slamon Dennis J.
Published: April 2023

PDF - 69K, Supplemental Figure Legend
Supplementary Figure 2 from The HSP90 Inhibitor NVP-AUY922 Potently Inhibits Non–Small Cell Lung Cancer Growth
Authors: Garon Edward B. , Finn Richard S. , Hamidi Habib , Dering Judy , Pitts Sharon , Kamranpour Naeimeh , Desai Amrita J. , Hosmer Wylie , Ide Susan , Avsar Emin , Jensen Michael Rugaard , Quadt Cornelia , Liu Manway , Dubinett Steven M. , Slamon Dennis J.
Published: April 2023

PDF - 500K, Heatmap showing post-treatment gene expression differences based on NVP-AUY922 sensitivity
Supplementary Figure 4 from Overexpression of DDX43 Mediates MEK Inhibitor Resistance through RAS Upregulation in Uveal Melanoma Cells
Authors: Ambrosini Grazia , Khanin Raya , Carvajal Richard D. , Schwartz Gary K.
Published: April 2023

PDF file - 2608K, RAS mRNA is not affected by DDX43 depletion.
Supplementary Figure 3 from Overexpression of DDX43 Mediates MEK Inhibitor Resistance through RAS Upregulation in Uveal Melanoma Cells
Authors: Ambrosini Grazia , Khanin Raya , Carvajal Richard D. , Schwartz Gary K.
Published: April 2023

PDF file - 766K, DDX43 is silenced with a second siRNA.
Supplemental Figure 1 from Clinical Utility of a Blood-Based BRAFV600E Mutation Assay in Melanoma
Authors: Panka David J. , Buchbinder Elizabeth , Giobbie-Hurder Anita , Schalck Aislyn P. , Montaser-Kouhsari Laleh , Sepehr Alireza , Lawrence Donald P. , McDermott David F. , Cohen Rachel , Carlson Alexander , Wargo Jennifer A. , Merritt Ryan , Seery Virginia J. , Hodi F. Stephen , Gunturi Anasuya , Fredrick Dennie , Atkins Michael B. , Iafrate A. John , Flaherty Keith T. , Mier James W. , Sullivan Ryan J.
Published: April 2023

BRAFV600E levels in patients with detectable BRAFV600E mutation in tissue who had peripheral blood cell isolation using CPT tubes vs Ficoll.
Supplementary Methods, Figure Legend from NF-κB Inhibition by Bortezomib Permits IFN-γ–Activated RIP1 Kinase–Dependent Necrosis in Renal Cell Carcinoma
Authors: Thapa Roshan J. , Chen Peirong , Cheung Mitchell , Nogusa Shoko , Pei Jianming , Peri Suraj , Testa Joseph R. , Balachandran Siddharth
Published: April 2023

PDF file - 110K
Supplementary Figure 3 from NF-κB Inhibition by Bortezomib Permits IFN-γ–Activated RIP1 Kinase–Dependent Necrosis in Renal Cell Carcinoma
Authors: Thapa Roshan J. , Chen Peirong , Cheung Mitchell , Nogusa Shoko , Pei Jianming , Peri Suraj , Testa Joseph R. , Balachandran Siddharth
Published: April 2023

PDF file - 457K, Supplementary Figure 3. Elevated NF-κB survival gene expression in RCC tumors.
Supplementary Figure 7 from Antitumor Activity of the Glutaminase Inhibitor CB-839 in Triple-Negative Breast Cancer
Authors: Gross Matt I. , Demo Susan D. , Dennison Jennifer B. , Chen Lijing , Chernov-Rogan Tania , Goyal Bindu , Janes Julie R. , Laidig Guy J. , Lewis Evan R. , Li Jim , MacKinnon Andrew L. , Parlati Francesco , Rodriguez Mirna L.M. , Shwonek Peter J. , Sjogren Eric B. , Stanton Timothy F. , Wang Taotao , Yang Jinfu , Zhao Frances , Bennett Mark K.
Published: April 2023

PDF - 113K, Supplementary Figure S7. Oral dosing of CB-839 results in high exposure in mouse plasma and is well tolerated in immunocompromised mice.
Supplementary Figures 1 - 2 from Therapeutic Silencing of KRAS Using Systemically Delivered siRNAs
Authors: Pecot Chad V. , Wu Sherry Y. , Bellister Seth , Filant Justyna , Rupaimoole Rajesha , Hisamatsu Takeshi , Bhattacharya Rajat , Maharaj Anshumaan , Azam Salma , Rodriguez-Aguayo Cristian , Nagaraja Archana S. , Morelli Maria Pia , Gharpure Kshipra M. , Waugh Trent A. , Gonzalez-Villasana Vianey , Zand Behrouz , Dalton Heather J. , Kopetz Scott , Lopez-Berestein Gabriel , Ellis Lee M. , Sood Anil K.
Published: April 2023

Supplementary figure 1 provides a schematic of DOPC:siRNA nanoliposomal preparation, and Supplementary figure 2 shows tumor volumetric measurements of the A549 orthotopic lung cancer therapeutic experiment described in the main figure 2.
Supplementary Figure 3 from Antitumor Activity of the Glutaminase Inhibitor CB-839 in Triple-Negative Breast Cancer
Authors: Gross Matt I. , Demo Susan D. , Dennison Jennifer B. , Chen Lijing , Chernov-Rogan Tania , Goyal Bindu , Janes Julie R. , Laidig Guy J. , Lewis Evan R. , Li Jim , MacKinnon Andrew L. , Parlati Francesco , Rodriguez Mirna L.M. , Shwonek Peter J. , Sjogren Eric B. , Stanton Timothy F. , Wang Taotao , Yang Jinfu , Zhao Frances , Bennett Mark K.
Published: April 2023

PDF - 126K, Supplementary Figure S3. TNBC primary tumors and cell lines have elevated glutaminase (GAC) mRNA levels.